BillionToOne Q2 revenue $109.4M (+64% YoY); net income $8.1M; reiterates FY guidance $450-465M

BillionToOne, Inc.

Revenue $109.4M (+64% YoY); prenatal $94.2M (+55%), oncology $13.7M (+176%).
Gross margin 70% (vs 65%); operating income $5.5M vs loss of $1.6M; net income $8.1M ($0.15 EPS).
196,000 tests delivered (+35%); free cash flow $5.1M.
Reiterates FY2026 revenue guidance $450M-$465M (48-52% growth).
Announces expanded Unity Fetal Risk Screen (130-gene panel) and Northstar Origin launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.